{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:31:51Z","timestamp":1791466311536,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/cgt.2016.11","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T10:21:46Z","timestamp":1460715706000},"page":"168-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer"],"prefix":"10.1038","volume":"23","author":[{"given":"R","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"BFcgt201611_CR1","first-page":"488","volume":"13","author":"W Chen","year":"2010","unstructured":"Chen W, Zhang S, Zou X . Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi 2010; 13: 488\u2013493.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"BFcgt201611_CR2","first-page":"1","volume":"8","author":"L XY","year":"2001","unstructured":"XY L . A new anticancer strategy-gene-virotherapy of cancer. Chin J Cancer Biother 2001; 8: 1.","journal-title":"Chin J Cancer Biother"},{"key":"BFcgt201611_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.cr.7290191","volume":"13","author":"ZL Zhang","year":"2003","unstructured":"Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13: 481\u2013489.","journal-title":"Cell Res"},{"key":"BFcgt201611_CR4","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1158\/0008-5472.CAN-04-1229","volume":"64","author":"Q Zhang","year":"2004","unstructured":"Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004; 64: 5390\u20135397.","journal-title":"Cancer Res"},{"key":"BFcgt201611_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.59566\/IJBS.2012.8087","volume":"8","author":"XY Liu","year":"2012","unstructured":"Liu XY . The excellent anti-tumour strategy (CTGVT, OV-gene) and the excellent anti-tumor gene (IL-24). Int J Biome Sci 2012; 8: 87\u201393.","journal-title":"Int J Biome Sci"},{"key":"BFcgt201611_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/sj.cr.7310108","volume":"16","author":"XY Liu","year":"2006","unstructured":"Liu XY . Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006; 16: 879\u2013886.","journal-title":"Cell Res"},{"key":"BFcgt201611_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ymthe.2004.12.003","volume":"11","author":"XY Liu","year":"2005","unstructured":"Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11: 531\u2013541.","journal-title":"Mol Ther"},{"key":"BFcgt201611_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.cgt.7700969","volume":"13","author":"L Zhao","year":"2006","unstructured":"Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006; 13: 1011\u20131022.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201611_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1089\/hum.2011.159","volume":"23","author":"SB Wang","year":"2012","unstructured":"Wang SB, Tan Y, Lei W, Wang YG, Zhou XM, Jia XY et al. Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect. Hum Gene Ther 2012; 23: 992\u20131002.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201611_CR10","first-page":"847","volume":"33","author":"ZQ Hang","year":"2011","unstructured":"Hang ZQ, Zheng MF, Huang JH . Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients. Zhonghua Zhong Liu Za Zhi 2011; 33: 847\u2013849.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"BFcgt201611_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6947-12-14","volume":"12","author":"CJ Verberne","year":"2012","unstructured":"Verberne CJ, Nijboer CH, de Bock GH, Grossmann I, Wiggers T, Havenga K . Evaluation of the use of decision-support software in carcino-embryonic antigen (CEA)-based follow-up of patients with colorectal cancer. BMC Med Inform Decis Mak 2012; 12: 1\u20135.","journal-title":"BMC Med Inform Decis Mak"},{"key":"BFcgt201611_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4103\/0973-1482.151538","volume":"10","author":"YR Wang","year":"2014","unstructured":"Wang YR, Yan JX, Wang LN . The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J Cancer Res Ther 2014; 10: 307\u2013309.","journal-title":"J Cancer Res Ther"},{"key":"BFcgt201611_CR13","doi-asserted-by":"publisher","first-page":"10547","DOI":"10.1007\/s13277-014-2355-5","volume":"35","author":"H Lai","year":"2014","unstructured":"Lai H, Jin Q, Lin Y, Mo X, Li B, He K . Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer. Tumour Biol 2014; 35: 10547\u201310554.","journal-title":"Tumour Biol"},{"key":"BFcgt201611_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","volume":"76","author":"M Grunnet","year":"2012","unstructured":"Grunnet M, Sorensen JB . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012; 76: 138\u2013143.","journal-title":"Lung Cancer"},{"key":"BFcgt201611_CR15","first-page":"9506","volume":"8","author":"W Zhao","year":"2015","unstructured":"Zhao W, Yu H, Han Z, Gao N, Xue J, Wang Y . Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer. Int J Clin Exp Pathol 2015; 8: 9506\u20139511.","journal-title":"Int J Clin Exp Pathol"},{"key":"BFcgt201611_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cca.2011.01.028","volume":"412","author":"DH Yu","year":"2011","unstructured":"Yu DH, Li JH, Wang YC, Xu JG, Pan PT, Wang L . Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin Chim Acta 2011; 412: 930\u2013935.","journal-title":"Clin Chim Acta"},{"key":"BFcgt201611_CR17","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1007\/s13277-015-3269-6","volume":"36","author":"F Facchinetti","year":"2015","unstructured":"Facchinetti F, Aldiqeri R, Aloe R, Bortesi B, Ardizzoni A, Tiseo M . CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients. Tumour Biol 2015; 36: 5943\u20135951.","journal-title":"Tumour Biol"},{"key":"BFcgt201611_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/icvts\/ivv085","volume":"21","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Horio H, Hato T, Harada M, Matsutani N, Kawamura M . Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected. Intera Cardiovas Thorac Surg 2015; 21: 14\u201320.","journal-title":"Intera Cardiovas Thorac Surg"},{"key":"BFcgt201611_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155\u2013162.","journal-title":"J Clin Invest"},{"key":"BFcgt201611_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/science.276.5309.111","volume":"276","author":"G Pan","year":"1997","unstructured":"Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111\u2013113.","journal-title":"Science"},{"key":"BFcgt201611_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ijc.20982","volume":"116","author":"H Ma","year":"2005","unstructured":"Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D et al. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 2005; 116: 314\u2013321.","journal-title":"Int J Cancer"},{"key":"BFcgt201611_CR22","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/0008-5472.CAN-04-2749","volume":"65","author":"J Shi","year":"2005","unstructured":"Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687\u20131692.","journal-title":"Cancer Res"},{"key":"BFcgt201611_CR23","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/0008-5472.CAN-05-1834","volume":"66","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 2006; 66: 4291\u20134298.","journal-title":"Cancer Res"},{"key":"BFcgt201611_CR24","first-page":"361","volume":"2","author":"C Weydert","year":"2003","unstructured":"Weydert C, Roling B, Liu J, Hinkhouse MM, Ritchie JM, Oberley LW et al. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther 2003; 2: 361\u2013369.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201611_CR25","doi-asserted-by":"publisher","first-page":"7758","DOI":"10.1128\/MCB.25.17.7758-7769.2005","volume":"25","author":"L Behrend","year":"2005","unstructured":"Behrend L, Mohr A, Dick T, Zwacha RM . Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol 2005; 25: 7758\u20137769.","journal-title":"Mol Cell Biol"},{"key":"BFcgt201611_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cbr.2014.1642","volume":"29","author":"F Huang","year":"2014","unstructured":"Huang F, Ma B, Wang Y, Xiao R, Kong Y, Zhou X et al. Targeting gene-virus-mediated manganese superoxide dismutase effectively suppresses tumor growth in hepatocellular carcinoma in vitro and in vivo. Cancer Biother Radiopharm 2014; 29: 403\u2013411.","journal-title":"Cancer Biother Radiopharm"},{"key":"BFcgt201611_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/02841860701403053","volume":"47","author":"Q Pan","year":"2008","unstructured":"Pan Q, Liu B, Liu J, Cai R, Liu X, Qian C . Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol 2008; 47: 135\u2013144.","journal-title":"Acta Oncol"},{"key":"BFcgt201611_CR28","doi-asserted-by":"publisher","first-page":"36152","DOI":"10.1074\/jbc.C000533200","volume":"275","author":"SM Srinivasula","year":"2000","unstructured":"Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES . Molecular determinants of the caspase-promoting activity of Smac\/DIABLO and its role in the death receptor pathway. J Biol Chem 2000; 275: 36152\u201336157.","journal-title":"J Biol Chem"},{"key":"BFcgt201611_CR29","first-page":"535","volume":"44","author":"Y Cai","year":"2012","unstructured":"Cai Y, Liu X, Huang W, Zhang K, Liu XY . Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim Biophys Sin(Shanghai) 2012; 44: 535\u2013543.","journal-title":"Acta Biochim Biophys Sin(Shanghai)"},{"key":"BFcgt201611_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.20203","volume":"39","author":"Z Pei","year":"2004","unstructured":"Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371\u20131381.","journal-title":"Hepatology"},{"key":"BFcgt201611_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00432-011-1138-2","volume":"138","author":"G He","year":"2012","unstructured":"He G, Lei W, Wang S, Xiao R, Guo K, Xia Y et al. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol 2012; 138: 657\u2013670.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFcgt201611_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/mp100219n","volume":"8","author":"S Pesonen","year":"2011","unstructured":"Pesonen S, Kanqasniemi L, Hemminki A . Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8: 12\u201328.","journal-title":"Mol Pharm"},{"key":"BFcgt201611_CR33","doi-asserted-by":"crossref","first-page":"13564","DOI":"10.18632\/oncotarget.3769","volume":"6","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu T, Huang P, Zhao H, Zhang R, Ma B et al. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget 2015; 6: 13564\u201313578.","journal-title":"Oncotarget"},{"key":"BFcgt201611_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1471-2407-13-254","volume":"13","author":"O Arrieta","year":"2013","unstructured":"Arrieta O, Villarreal-Garza C, Martinez-Barrera L, Morales M, Dorantes-Gallareta Y, Pena-Curiel O et al. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study. BMC Cancer 2013; 13: 254.","journal-title":"BMC Cancer"},{"key":"BFcgt201611_CR35","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.7314\/APJCP.2015.16.17.7809","volume":"16","author":"M Tomita","year":"2015","unstructured":"Tomita M, Ayabe T, Chosa E, Nakamura K . Postoperative serum CEA level is a more significant prognostic factor than post\/preoperative serum CEA ratio in non-small cell cancer patients. Asian Pac J Cancer Prev 2015; 16: 7809\u20137812.","journal-title":"Asian Pac J Cancer Prev"},{"key":"BFcgt201611_CR36","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.3390\/v7122938","volume":"7","author":"S Turnbull","year":"2015","unstructured":"Turnbull S, West EJ, Scott KJ, Appleton E, Melcher A, Ralph C . Evidence for oncolytic virotherapy: where have we got to and where are we going? Viruses 2015; 7: 6291\u20136312.","journal-title":"Viruses"},{"key":"BFcgt201611_CR37","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780\u20132688.","journal-title":"J Clin Oncol"},{"key":"BFcgt201611_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2015.09.014","volume":"28","author":"DR Holohan","year":"2015","unstructured":"Holohan DR, Lee JC, Bluestone JA . Shifting the evolving CAR T cell platform into higher gear. Cancer Cell 2015; 28: 401\u2013402.","journal-title":"Cancer Cell"},{"key":"BFcgt201611_CR39","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194: 950\u2013959.","journal-title":"J Immunol"},{"key":"BFcgt201611_CR40","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558\u2013562.","journal-title":"Nature"},{"key":"BFcgt201611_CR41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.18632\/oncotarget.1430","volume":"5","author":"W Wang","year":"2014","unstructured":"Wang W, Ji W, Hu H, Ma J, Li X, Mei W et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy. Oncotarget 2014; 5: 150\u2013160.","journal-title":"Oncotarget"},{"key":"BFcgt201611_CR42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/aps.2012.196","volume":"34","author":"W Lei","year":"2013","unstructured":"Lei W, Liu HB, Wang SB, Zhou XM, Zheng SD, Guo KN et al. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model. Acta Pharmacol Sin 2013; 34: 531\u2013540.","journal-title":"Acta Pharmacol Sin"},{"key":"BFcgt201611_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00432-014-1835-8","volume":"141","author":"B Ma","year":"2015","unstructured":"Ma B, Wang Y, Zhou X, Huang P, Zhang R, Liu T et al. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. J Cancer Res Clin Oncol 2015; 141: 419\u2013429.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201611","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T19:55:35Z","timestamp":1718481335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFcgt201611"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2016.11","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]},"assertion":[{"value":"13 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}